A biopharmaceutical company based in Hong Kong that discovers and sells targeted cancer therapies and immunotherapies, working with global partners such as Takeda and Eli Lilly. Its best-known product, Fruzaqla, is an oral pill for advanced colorectal cancer approved by U.S. and European regulators. The company began in 2000 as Hutchison China MediTech (nicknamed Chi-Med), a spin-off of the pharmaceutical arm of Hong Kong's Hutchison Whampoa conglomerate, and rebranded to HUTCHMED in 2021. Its name combines the Hutchison family legacy with "Med" for medicine.
HUTCHMED discloses insolvency of S.D. Sight, a company formerly directed by its Chairman Dr Dan Eldar.
S.D. Sight is an Israeli medical device company developing a computer vision platform for diagnosing blood diseases; Dr Eldar was a director from December 20, 2018 to March 18, 2026.
Show detailsHide details
Dr Dan Eldar, Chairman and Non-executive Director of HUTCHMED, notified the board that S.D. Sight Diagnostics Ltd. became subject to insolvency proceedings in Israel.
Hutchison Water Israel E.P.C Ltd, where Dr Eldar is an executive director, holds approximately 9.98% of S.D. Sight and nominated Dr Eldar to its board; neither entity is part of HUTCHMED's group.
Insolvency proceedings began with an application on April 12, 2026, a court order on May 24, 2026, and a trustee appointment on May 28, 2026; the amount involved is approximately NIS3,057,876 (US$1,019,292).
The company states the proceedings do not involve the Group and are not expected to impact its businesses or operations.
HUTCHMED's ORPATHYS plus TAGRISSO improves survival in MET-driven EGFR-mutated lung cancer in Phase III SAFFRON trial.
SAFFRON Phase III trial met primary endpoint: ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) showed statistically significant improvement in progression-free survival (PFS) versus platinum-based chemotherapy.
Show detailsHide details
The combination also demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) in patients with MET overexpression/amplification after progression on TAGRISSO.
Trial enrolled 338 patients across 230 centers in 29 countries; safety profile was consistent with known profiles of each medicine with no new safety findings.
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities to support global registrations.
ORPATHYS plus TAGRISSO is already approved in China for this setting based on the SACHI Phase III trial.
HUTCHMED's ORPATHYS® (savolitinib) gets NMPA conditional approval for MET-amplified gastric cancer in China.
China's NMPA granted conditional approval for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification after at least two prior systemic treatments.
Show detailsHide details
This is the first selective MET inhibitor approved for this patient population in China and the third approved indication for ORPATHYS® in China.
The approval is based on a pivotal Phase II study (NCT04923932) that met its primary endpoint with an IRC-assessed objective response rate of 32.3% (95% CI: 21.2%, 45.1%) as of October 8, 2025.
Secondary endpoints included a disease control rate of 63.1%, median time to response of 1.4 months, median duration of response of 9.7 months, and median progression-free survival of 4.0 months.
ORPATHYS® is jointly developed with AstraZeneca, which commercializes the drug in China; it has been on China's National Reimbursement Drug List since March 2023.
HUTCHMED reports blocklisting six monthly return with 43.6M new shares under 2026 scheme
HUTCHMED (China) Limited filed a Form 6-K on June 29, 2026, covering the period from December 29, 2025 to June 28, 2026.
Show detailsHide details
The 2015 Share Option Scheme had a balance of 45,775,868 ordinary shares at the start, with 7,500 shares issued during the period, leaving 45,768,368 shares unissued.
The 2026 Share Option Scheme, adopted at the annual general meeting on May 12, 2026, added 43,616,756 ordinary shares, with no shares issued during the period.
Total ordinary shares in issue at the end of the period were 872,335,120.
The 2026 scheme's shares were admitted to listing on June 11, 2026.
HUTCHMED reports pivotal Phase II data for fanregratinib in ICC at ESMO GI 2026
Pivotal Phase II study of fanregratinib in intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusions/rearrangements met primary endpoint with IRC-assessed ORR of 42.5%.
Show detailsHide details
Median duration of response was 6.9 months, disease control rate 83.9%, median progression-free survival 6.9 months, and median overall survival 16.6 months.
NDA for fanregratinib in this indication was accepted and granted priority review by China's NMPA in December 2025.
Safety profile was manageable; Grade 3+ drug-related adverse events in 48.3% of patients, discontinuation rate 2.2%, no treatment-related deaths.
Data presented at ESMO Gastrointestinal Cancers Congress 2026 in Munich, July 1-4, 2026.